RWD164 Real-World Prevalence of Genetic Mutations in Female Breast Cancer Patients Aged =65 Years in the US between 2014 and 2022

Abstract

Genetic mutations in ERBB2, TP53, PIK3CA, BRAF, EGFR and KRAS are linked to a higher susceptibility for developing breast cancer. Thus, genetic evaluation is a critical part of patient care. This study evaluated differences in U.S. age demographics and genotype testing in a real-world population of patients with advanced breast cancer (ABC) between 2014 and 2022.